antibody-drug conjugate

Regeneron stays out of ADC deal fray as in-house scientists tinker
Regeneron stays out of ADC deal fray as in-house scientists tinker
Fierce Biotech
Regeneron
antibody-drug conjugate
Flag link:
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
Motley Fool
Merck
Bristol Myers Squibb
antibody-drug conjugate
Flag link:
Bristol Myers pays $100M for a different kind of ADC
Bristol Myers pays $100M for a different kind of ADC
BioPharma Dive
Bristol Myers Squibb
antibody-drug conjugate
bone cancer
blood cancer
Orum Therapeutics
Flag link:
Daiichi-Sankyo ups revenue forecast thanks to massive Merck deal
Daiichi-Sankyo ups revenue forecast thanks to massive Merck deal
Fierce Biotech
Daiichi Sankyo
Merck
antibody-drug conjugate
Flag link:
‘We knew it was there’: AbbVie CEO says company favored internal work over potential Daiichi deal
‘We knew it was there’: AbbVie CEO says company favored internal work over potential Daiichi deal
Fierce Biotech
AbbVie
Daiichi Sankyo
Merck
antibody-drug conjugate
Flag link:
ESMO: Ambrx's 'reset' arrives at the last line of prostate cancer, offering the kind of safety rarely seen
ESMO: Ambrx's 'reset' arrives at the last line of prostate cancer, offering the kind of safety rarely seen
Fierce Biotech
ESMO
Ambrx
prostate cancer
ARX517
antibody-drug conjugate
Flag link:
In 2nd big ADC deal of the day, GSK inks $2B-plus pact for Hansoh gynecology cancer asset
In 2nd big ADC deal of the day, GSK inks $2B-plus pact for Hansoh gynecology cancer asset
Fierce Biotech
GSK
antibody-drug conjugate
Hansoh Pharmaceutical
Flag link:
ESMO: Seagen and Genmab's Tivdak keeps cervical cancer patients alive longer
ESMO: Seagen and Genmab's Tivdak keeps cervical cancer patients alive longer
Fierce Pharma
ESMO
Pfizer
Seagen
cervical cancer
antibody-drug conjugate
Flag link:
Merck pays $4B upfront for rights to 3 Daiichi ADCs in huge bet on post-Keytruda future
Merck pays $4B upfront for rights to 3 Daiichi ADCs in huge bet on post-Keytruda future
Fierce Biotech
Merck
Daiichi Sankyo
AstraZeneca
antibody-drug conjugate
Flag link:
Lilly links up European ADC network, snagging Elahere rival in latest biotech buy
Lilly links up European ADC network, snagging Elahere rival in latest biotech buy
Fierce Biotech
Eli Lilly
M&A
antibody-drug conjugate
Elahere
Mablink
Flag link:
BioNTech Inks Potential $1B Deal with MediLink for Cancer-Focused ADCs
BioNTech Inks Potential $1B Deal with MediLink for Cancer-Focused ADCs
BioSpace
BioNTech
MediLink
cancer
antibody-drug conjugate
Flag link:
BioNTech takes another leaf out of Daiichi playbook, paying $70M for HER3-directed ADC
BioNTech takes another leaf out of Daiichi playbook, paying $70M for HER3-directed ADC
Fierce Biotech
BioNTech
Daiichi Sankyo
antibody-drug conjugate
breast cancer
Flag link:
AstraZeneca, Daiichi Tout Phase III Breast Cancer Data in Challenge to Gilead
AstraZeneca, Daiichi Tout Phase III Breast Cancer Data in Challenge to Gilead
BioSpace
AstraZeneca
Daiichi Sankyo
breast cancer
antibody-drug conjugate
clinical trials
Flag link:
AstraZeneca, Daiichi Sankyo show off ADC portfolio with safety top of mind
AstraZeneca, Daiichi Sankyo show off ADC portfolio with safety top of mind
Fierce Biotech
AstraZeneca
Daiichi Sankyo
antibody-drug conjugate
non-small cell lung cancer
Dato-DXd
Flag link:
Nurix and Seagen Collaborate on Breakthrough Cancer Therapeutics
Nurix and Seagen Collaborate on Breakthrough Cancer Therapeutics
Globe Newswire
Nurix Therapeutics
Seagen
protein degradation
cancer
antibody-drug conjugate
Flag link:
AbbVie Removes Two Early-Stage Cancer Assets from Pipeline
AbbVie Removes Two Early-Stage Cancer Assets from Pipeline
BioSpace
AbbVie
antibody-drug conjugate
cancer
Flag link:
Former Big Pharma darling Atreca axes lead drug, 40% of staff in last-ditch pivot to ADCs
Former Big Pharma darling Atreca axes lead drug, 40% of staff in last-ditch pivot to ADCs
Fierce Biotech
Atreca
antibody-drug conjugate
layoffs
Flag link:
Sutro strengthens its immuno-oncology pipeline with two new ADCs
Sutro strengthens its immuno-oncology pipeline with two new ADCs
Clinical Trials Arena
Sutro BioPharma
immuno-oncology
antibody-drug conjugate
Flag link:
Seagen, Merck put $1.6B ADC collab on the back burner citing 'emerging treatment landscape'
Seagen, Merck put $1.6B ADC collab on the back burner citing 'emerging treatment landscape'
Fierce Biotech
Seagen
Merck
antibody-drug conjugate
Flag link:
ImmunoGen Inks Cancer ADC Partnership with ImmunoBiochem
ImmunoGen Inks Cancer ADC Partnership with ImmunoBiochem
BioSpace
Immunogen
ImmunoBiochem
cancer
antibody-drug conjugate
Flag link:

Pages